Carsten Koall/Getty Images News
- Novavax (NASDAQ:NVAX) announced Wednesday that the U.K. regulators granted full marketing authorization for its prototype COVID-19 vaccine, Nuvaxovid, for those aged 12 years and older.
- According to NVAX, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) decided to fully approve Nuvaxovid based on data from Phase 2 and Phase 3 trials the company conducted for the protein-based shot in countries including the U.S. and U.K.
- “Full marketing authorization of our prototype COVID-19 vaccine in the U.K. is a stepping stone to enable authorization of updated strains of our vaccine in the future,” CEO John Jacobs remarked.
- Jacobs added that the company is working with the MHRA to ensure the agency has enough information to review the company’s updated COVID shot in time for the U.K.’s upcoming immunization drive.
